Faye M. Johnson
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Year:
2026
Background Human papillomavirus (HPV)-driven cancers include head and neck squamous cell carcinoma and cervical cancer and represent approximately 5% of all cancer cases worldwide. Standard-of-care chemotherapy, radiotherapy, and immune checkpoint inhibitors (ICIs) are associated with adverse effects and limited responses in patients with HPV-driven cancers. The integration of targeted therapies with ICIs may improve outcomes. In a previous study, we demonstrated that Aurora kinase A ( AURKA , Aurora A) inhibitors lead to apoptosis of human HPV-positive cancer cells in vitro and in vivo. Here, we explored the potential of Aurora A inhibition to enhance response to ICIs in immune-competent preclinical models of HPV-driven cancers. Methods We assessed the induction of apoptosis, DNA damage, and immunogenic cell death (ICD) in response to treatment with the Aurora A inhibitor alisertib in vitro and antitumor efficacy of alisertib as a monotherapy and in combination with ICIs that inhibit programmed cell death protein-1 (PD-1) or cytotoxic T-lymphocyte associated protein 4 (CTLA-4) in murine HPV-positive immune-competent tumor models. In each treatment group, we determined the tumor growth kinetics and long-term survival and assessed the tumor immune microenvironment using polychromatic flow cytometry. Results Aurora A inhibition induced apoptosis, DNA damage, and ICD in vitro in multiple human and murine HPV-positive cancer cell lines. Importantly, Aurora A inhibition induced selective apoptotic depletion of myeloid-derived suppressor cells (MDSCs). In vivo experiments demonstrated that the combination of alisertib with ICIs, specifically anti-CTLA4, resulted in improved survival outcomes by altering the tumor immune microenvironment. This combination enhanced CD8 T-cell infiltration and decreased the frequencies of MDSCs, whereas neither alisertib nor ICIs (anti-PD-1/anti-CTLA-4) alone showed such effects. Conclusion Our study establishes the potential of Aurora A inhibition to sensitize HPV-positive tumors to ICIs, specifically anti-CTLA-4 treatment. This combination strategy resulted in enhanced antitumor efficacy, driven by systemic and intratumoral increases in CD8 T-cell responses and reduced immunosuppressive cell populations, specifically MDSCs. These findings offer insights into the synergistic effects of Aurora A inhibition and ICIs and argue for further investigation and optimization of this combination approach in HPV-driven cancers.
Year:
2025
Purpose: Effective therapy for recurrent head and neck squamous cell carcinoma (HNSCC) that is refractory to chemotherapy and immunotherapy is a considerable need. Aurora kinase A inhibition leads to apoptosis and immunogenic cell death in preclinical models of human papilloma virus (HPV)–driven cancers. Patients and Methods: Alisertib was administered orally twice daily on days 1–7 and pembrolizumab on day 1 of a 21-day cycle to adults with advanced solid tumors (phase I) or with immunotherapy- and platinum-resistant, HPV-positive HNSCC (phase II). Results: The recommended phase II alisertib dose was 40 mg, which had only the expected toxicity including cytopenia that led to dose reductions in two phase II patients at cycles 13 and 16. We saw no objective responses, but the combination led to prolonged stable disease (SD) in several patients, including two of 10 phase I patients (8 and 27 months). Eight of the 15 HPV-positive patients had SD, of which four (heavily pretreated) had ≥6 months, with median overall and progression-free survival durations of 16.8 and 1.4 months, respectively. In circulating immune cells and plasma, patients with SD had markedly higher levels of HLA de novo resistance–expressing NK cells than did progressive disease patients who demonstrated a more immunosuppressive and inflammatory profile. Pharmacokinetics did not indicate any significant drug-drug interactions between pembrolizumab and alisertib. Conclusions: The combination of alisertib and pembrolizumab was well tolerated and led to prolonged SD in some immunotherapy-resistant patients, supporting our hypothesis that Aurora kinase A inhibition can reverse immunotherapy resistance of retinoblastoma protein–deficient HNSCC.
Year:
2025
Year:
2025
We identified frequent inactivating notch1 mutations in HNSCC over a decade ago, indicating its role as a tumor suppressor—unlike its oncogenic function in leukemias and salivary gland tumors. However, there has been much debate in the literature regarding a possible oncogenic role in HNSCC as well, based on reports that notch1 signaling drives tumor growth and a cancer stem cell phenotype in some HNSCC tumor lines and patient samples. Clarifying whether NOTCH1 occasionally functions as an oncogenic driver in HNSCC is crucial to the prognosis and personalized therapy of patients with either wild-type or mutated NOTCH1. Here we present a systematic and comprehensive investigation unequivocally demonstrating that notch1 signaling functions as a tumor suppressor in HNSCC regardless of mutation or activation status and leads to reduction in frequency of cancer stem cells. We develop a robust gene expression signature of notch1 activation based on experimental data that when applied to patient samples shows notch1 signaling is associated with very early differentiation, an altered tumor microenvironment, and better prognosis— consistent with a tumor suppressive role. Our work unifies the field by reconciling conflicting data and providing critical insights into the biological and clinical significance of the NOTCH1 pathway in HNSCC.
Year:
2025
Purpose: Effective therapy for recurrent head and neck squamous cell carcinoma (HNSCC) that is refractory to chemotherapy and immunotherapy is a considerable need. Aurora kinase A inhibition leads to apoptosis and immunogenic cell death in preclinical models of human papilloma virus (HPV)–driven cancers. Patients and Methods: Alisertib was administered orally twice daily on days 1–7 and pembrolizumab on day 1 of a 21-day cycle to adults with advanced solid tumors (phase I) or with immunotherapy- and platinum-resistant, HPV-positive HNSCC (phase II). Results: The recommended phase II alisertib dose was 40 mg, which had only the expected toxicity including cytopenia that led to dose reductions in two phase II patients at cycles 13 and 16. We saw no objective responses, but the combination led to prolonged stable disease (SD) in several patients, including two of 10 phase I patients (8 and 27 months). Eight of the 15 HPV-positive patients had SD, of which four (heavily pretreated) had ≥6 months, with median overall and progression-free survival durations of 16.8 and 1.4 months, respectively. In circulating immune cells and plasma, patients with SD had markedly higher levels of HLA de novo resistance–expressing NK cells than did progressive disease patients who demonstrated a more immunosuppressive and inflammatory profile. Pharmacokinetics did not indicate any significant drug-drug interactions between pembrolizumab and alisertib. Conclusions: The combination of alisertib and pembrolizumab was well tolerated and led to prolonged SD in some immunotherapy-resistant patients, supporting our hypothesis that Aurora kinase A inhibition can reverse immunotherapy resistance of retinoblastoma protein–deficient HNSCC.
Year:
2025
Supplementary Figure S7. Flow cytometry analyses of circulating lymphocyte subsets in patients with acquired resistance (AR, n =8) or de novo resistance (DR, n=4) to prior anti-PD1 immunotherapy.
Year:
2025
Supplementary Figure S6. Plasma samples collected at the baseline from the participants of the trial were compared between the PD and SD groups of patients by the Luminex analyses to profile various cytokines and chemokines.
Year:
2025
Purpose: Neoadjuvant chemotherapy prior to definitive surgery has been used widely for locally advanced oral squamous cell carcinoma (OSCC). We evaluated neoadjuvant erlotinib with platinum-docetaxel versus placebo with platinum-docetaxel in patients with stage IIIIVB OSCC. Patients and Methods: Patients with newly diagnosed stage III, IVA, and IVB (American Joint Committee on Cancer 7th) OSCC amenable to surgical resection were included. Patients were randomized to receive up to 3 cycles of chemotherapy with concurrent erlotinib or placebo, followed by surgery. The primary endpoint was major pathologic response (MPR) rate; secondary endpoints included safety, overall survival (OS), and progression-free survival (PFS). Results: Fifty-two patients received at least 1 cycle of treatment and 47 were evaluable with surgical resection. MPR rate was not different between erlotinib (30%, 7/23) and placebo arms (41.7%, 10/24; P = 0.55). At median follow up of 26.5 months, there was no difference on OS or PFS between groups. Patients who received erlotinib with chemotherapy and achieved MPR ( n = 7) had no recurrence. The treatment-related adverse event rates were not different between the two groups (96% vs. 96%). However, rash, mostly low grade, was more common in the erlotinib arm (79% vs. 50%). Transcriptomic analysis in the pretreatment samples indicated that genes in protein glycosylation and Wnt signaling pathways were associated with benefit in those treated with erlotinib plus chemotherapy. Conclusions: The addition of erlotinib to platinum-taxane chemotherapy was well tolerated but did not induce higher rates of MPR or PFS or OS survival benefit. Patients who received chemotherapy with erlotinib and achieved major pathologic responses had excellent clinical outcome.
Year:
2025
Objective Patients treated for oropharyngeal cancer (OPC) have historically demonstrated high feeding tube rates for decreased oral intake and malnutrition. We re‐examined feeding tube practices in these patients. Study Design Retrospective analysis of prospective cohort from 2015 to 2021. Setting Single‐institution NCI‐Designated Comprehensive Cancer Center. Methods With IRB approval, patients with new oropharyngeal squamous cell cancer or (unknown primary with neck metastasis) were enrolled. Baseline swallowing was assessed via videofluoroscopy and Performance Status Scale for Head and Neck Cancer (PSSHN). G‐tubes or nasogastric tubes (NGT) were placed for weight loss before, during, or after treatment. Prophylactic NGT were placed during transoral robotic surgery (TORS). Tube duration was censored at last disease‐free follow‐up. Multivariate regression was performed for G‐tube placement (odds ratio [OR] [95% confidence interval [CI]) and removal (Cox hazard ratio, hazard ratio [HR] [95% CI]). Results Of 924 patients, most had stage I to II (81%), p16+ (89%), node‐positive (88%) disease. Median follow‐up was 2.6 years (interquartile range 1.5‐3.9). Most (91%) received radiation/chemoradiation, and 16% received TORS. G‐tube rate was 27% (5% after TORS). G‐tube risk was increased with chemoradiation (OR 2.78 [1.87‐4.22]) and decreased with TORS (OR 0.31 [0.15‐0.57]) and PSSHN‐Diet score ≥60 (OR 0.26 [0.15‐0.45]). G‐tube removal probability over time was lower for T3 to T4 tumors (HR 0.52 [0.38‐0.71]) and higher for PSSHN‐Diet score ≥60 (HR 1.65 [1.03‐2.66]). Conclusions In this modern cohort of patients treated for OPC, 27% received G‐tubes—50% less than institutional rates 10 years ago. Patients with preserved baseline swallowing and/or those eligible for TORS may have lower G‐tube risk and duration.
Year:
2024
Year:
2022
Collaborators (21)
Xiuning Le
The University of Texas MD Anderson Cancer Center
Jagannadha Sastry
Research Associate - Professor
The University of Texas MD Anderson Cancer Center
Neil Gross
Professor
The University of Texas MD Anderson Cancer Center
Gordon Mills
Professor
Oregon Health & Science University
Jeffrey N. Myers
The University of Texas MD Anderson Cancer Center
Curtis R. Pickering
The University of Texas MD Anderson Cancer Center
Katherine Hutcheson
Associate Professor
The University of Texas MD Anderson Cancer Center
Hai Tran
Associate Professor
The University of Texas MD Anderson Cancer Center
Vlad Sandulache
Associate Professor
Baylor College of Medicine
Stephen Lai
Professor
The University of Texas MD Anderson Cancer Center
Amy Moreno
Assistant Professor
The University of Texas MD Anderson Cancer Center
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Jiexin Zhang
The University of Texas MD Anderson Cancer Center
Miriam Lango
Professor
The University of Texas MD Anderson Cancer Center
FREDERICO OMAR GLEBER NETTO
Assistant Professor
The University of Texas MD Anderson Cancer Center
LI SHEN
The University of Texas MD Anderson Cancer Center
Maura L. Gillison
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Alexandre Reuben
Assistant Professor
The University of Texas MD Anderson Cancer Center
Abdullah Osman
Associate Professor
The University of Texas MD Anderson Cancer Center
Clifton D Fuller
Professor (Tenured)
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.